Tysabri PML Cases Pose REMS Challenges To FDA
Two new cases of the brain infection could impact sales of the drug, particularly in the treatment naive multiple sclerosis setting.
Two new cases of the brain infection could impact sales of the drug, particularly in the treatment naive multiple sclerosis setting.